Jason Slakter, MD
Ophthalmology · New York, NYNPI 1275562084
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $270,931 of the $272,197 with a category attached, or 99.5%. Aerie Pharmaceuticals, Inc. accounts for 84.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $96,940 and has fallen 91.7% since, to $8,064 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $4462.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$229K
- Alcon$26K
- Apellis Pharmaceuticals, Inc.$11K
- AstraZeneca$4K
- GSK$3K
- AbbVie$64
- plus $136 from 3 others
Across 19 payments — averaging $50,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$467K
- Mylan Technologies Inc.$429K
- F. Hoffmann-la Roche AG$40K
- Mylan Inc.$20K
What the payments were for
- Consulting fees$270,931100%
- Food & beverage$1,2660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 30 | $228,635 |
| Alcon | 8 | $25,580 |
| Apellis Pharmaceuticals, Inc. | 15 | $10,886 |
| AstraZeneca | 1 | $4,296 |
| GSK | 1 | $2,600 |
| AbbVie | 2 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| Astellas Pharma Global Development | 1 | $41 |
| Genentech USA, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$593
How this compares
$272,197 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 30 | $887 |
| Prednisolone Acetate | 19 | $761 |
| Latanoprost | 21 | $388 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- David ChuNew York$234K
- Joshua KimNew York$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.